Skip to content
usa post click

Usa Post Click

Your Latest USA News

  • Home
  • Business
  • Culture
  • Education
  • Retail
  • Travel
  • Toggle search form

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Posted on December 22, 2022 By P.C. editor
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery PlatformGb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

LAS VEGAS - December 22, 2022 - (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses. 

The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences' CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.

"Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself," said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here. 

A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences' MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes," and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.


Contact Information:
Alexis Quintal
[email protected]


Press Release Service by Newswire.com

Original Source: Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Business

Post navigation

Previous Post: Following More Than a Decade of Development, TM Technologies Demonstrates More Than 50% Increase in Data Efficiency for Telecom
Next Post: Violet Defense Receiving Accreditation From American Institute of Architects

More Related Articles

Learn About Edison Aerospace Green Energy Solutions Business
Encinitas-Based Shoreline Recovery Center Seeing Increases in Patients Post Holiday Time Business
Dunlop Sports Launches New Global Websites Combining Golf Brands and Racket Sports Business
Dammam Commercial Centre: Dar Al Riyadh Sets New Trends of Smart Cities in the Kingdom of Saudi Arabia Business
Bona Fide Masks Corp., the Most Trusted Name in the Mask Industry, Reinforces Company Readiness for Demand Surges Due to Evasive COVID-19 Variants Business
Harold Bevis Joins the Committee for Economic Development (CED) as Trustee Business
February 2023
MTWTFSS
 12345
6789101112
13141516171819
20212223242526
2728 
« Jan    
  • Doggyland: Kids Songs & Nursery Rhymes, Starring and Co-Created by Snoop Dogg Lands on Kidoodle.TV®February 1, 2023
  • Cornell Rocketry Team and Valworx Announce Partnership for Competitive RocketFebruary 1, 2023
  • Impact Professionals Finds Success With Its Advertising-Based Video On-Demand ModelJanuary 31, 2023
  • Yahoo! Answers: Laser LevelJanuary 31, 2023
  • EU plans rollout of travel certificate before summer – BBC NewsJanuary 31, 2023
  • Lost Oak Winery Named a Top Texas Wedding Venue, Encourages Couples to Plan AheadJanuary 31, 2023
  • BAIMEI Releases New Face Coolers: Their Popular Face Roller Gua Sha Sets Come in Gifting-Ready Boxes, Making for Perfect Holiday GiftsJanuary 31, 2023
  • Magnus Financial Group Announces Chase Wickenheiser Has Joined the Firm as an AssociateJanuary 31, 2023
  • Impact 21 Introduces Scot Knox as Principal ConsultantJanuary 31, 2023
  • Lunge, the Dating App That Matches Singles at the Same Gym, Offcially LaunchesJanuary 31, 2023
  • Incident IQ Announces iiQ Events and New iiQ Facilities Enhancements at TCEA 2023January 31, 2023
  • Myriad Advisor Solutions Announces New CEOJanuary 31, 2023
  • BetterWork Media Group Launches Membership ProgramJanuary 31, 2023
  • Visit Hungary Announces New Hotel Openings in Budapest for 2023January 30, 2023
  • Ben Affleck and Matt Damon Make a Splash on Gossip Stone TVJanuary 30, 2023
publish press release online
VUGA Enterprises
24Fashion TV - best fashion shows and social network. Free membership
24Fashion TV
breaking celebrity news
Free Reality TV
laser med spa in miami
plastic surgery, stem cell clinic in kiev

Copyright © 2023 Usa Post Click.